Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Dense vs Metronomic Temozolomide in Glioblastoma
NCT00200161Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2005
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of temozolomide in glioblastoma (GBM) and malignant glioma (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Survival at 12 months. Started Aug 2005; status: completed.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)malignant glioma
Beyond the preview
Go deeper on NCT00200161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00200161.